Kristin Brooks05.18.21
BD (Becton, Dickinson and Company) is building a $200 million high-tech manufacturing facility in Zaragoza, located in the Aragon region of Spain, to support the production of pre-fillable syringes for vaccines and other biologics, that will create as many as 600 jobs by 2030.
Construction of the new plant will begin in late 2021, and will be the fourth manufacturing plant for BD in Spain. The site will initially have a workforce of 150 people and encompass an area of 86,000 square feet. By 2030 it is expected to employ up to 600 people with an area of 323,000 square feet. The new facility will incorporate eco-efficiency standards, and will be a fully digital site leveraging intelligent and autonomous technologies, also knowns as Industry 4.0 solutions.
“BD's new plant in Zaragoza will produce drug delivery devices, primarily for pharmaceutical companies that supply the European market with drugs in pre-fillable syringes such as vaccines and other biologic drugs,” said Eric Borin, worldwide president of BD Pharmaceutical Systems. “This new plant will also add needed capacity to support major vaccination campaigns, such as the one currently taking place in response to the COVID-19 pandemic.”
The new site represents a part of the $1.2 billion investment over four years to expand and upgrade manufacturing capacity and technology for pre-fillable syringes (PFS) and advanced drug delivery systems (ADDS) as part of BD’s 2025 growth strategy. Along with three production plants in San Agustín de Guadalix, Fraga and Almaraz, these facilities produce a total of 10 billion medical devices and employ 1,500 people. The Fraga plant is a key production site for the manufacture of COVID-19 vaccination injection devices.
Construction of the new plant will begin in late 2021, and will be the fourth manufacturing plant for BD in Spain. The site will initially have a workforce of 150 people and encompass an area of 86,000 square feet. By 2030 it is expected to employ up to 600 people with an area of 323,000 square feet. The new facility will incorporate eco-efficiency standards, and will be a fully digital site leveraging intelligent and autonomous technologies, also knowns as Industry 4.0 solutions.
“BD's new plant in Zaragoza will produce drug delivery devices, primarily for pharmaceutical companies that supply the European market with drugs in pre-fillable syringes such as vaccines and other biologic drugs,” said Eric Borin, worldwide president of BD Pharmaceutical Systems. “This new plant will also add needed capacity to support major vaccination campaigns, such as the one currently taking place in response to the COVID-19 pandemic.”
The new site represents a part of the $1.2 billion investment over four years to expand and upgrade manufacturing capacity and technology for pre-fillable syringes (PFS) and advanced drug delivery systems (ADDS) as part of BD’s 2025 growth strategy. Along with three production plants in San Agustín de Guadalix, Fraga and Almaraz, these facilities produce a total of 10 billion medical devices and employ 1,500 people. The Fraga plant is a key production site for the manufacture of COVID-19 vaccination injection devices.
